FIELD: biotechnology.
SUBSTANCE: invention relates to a composition containing a recombinant adeno-associated virus (AAV) vector containing an AAV capsid that encapsulates a nucleotide of interest, and a polyspecific binding molecule containing an antibody paratope that specifically binds a heterologous epitope, and a retargeting ligand, which specifically binds a cell surface protein or marker, as well as a method of delivering the nucleotide of interest to a target cell expressing the cell surface protein using it.
EFFECT: invention is effective for targeted introduction of genetic material into a cell.
43 cl, 15 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| ISOLATED MODIFIED VP1 CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON IT | 2019 |
|
RU2751592C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
